

Accepted Manuscript

Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea

Michael Camilleri, Joseph H. Sellin, Kim E. Barrett



PII: S0016-5085(16)35237-4
DOI: [10.1053/j.gastro.2016.10.014](https://doi.org/10.1053/j.gastro.2016.10.014)
Reference: YGAST 60776

To appear in: *Gastroenterology*
Accepted Date: 11 October 2016

Please cite this article as: Camilleri M, Sellin JH, Barrett KE, Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea, *Gastroenterology* (2016), doi: 10.1053/j.gastro.2016.10.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea**Michael Camilleri, *Joseph H. Sellin, and ^Kim E. Barrett**

Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER),
Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic,
Rochester, MN;

*Division of Gastroenterology, Department of Medicine, Baylor College of Medicine,
Houston, TX;

^Division of Gastroenterology, Department of Medicine, University of California, San Diego,
La Jolla, CA

Word count: 6400 (excludes abstract, acknowledgements, references, table and figure legends)

Funding: Work from the authors' laboratories have been supported by grants from the National Institutes of Health (M. Camilleri: R01-DK92179; K. Barrett: AI077661). Dr. Barrett has received an unrestricted grant from the Estratest/Shape Up settlement fund.

Disclosures: Dr. Camilleri has received support for single-center research studies from Salix, Novartis, and NGM Biopharmaceuticals for studies in diarrheal diseases. Dr. Barrett has nothing to disclose. Dr. Sellin discloses participation in clinical trials related to inflammatory bowel diseases.

Authors' contributions: M.Camilleri: co-authorship and coordination of manuscript; primary author on pathophysiology and secondary author on clinical section;
K.E. Barrett: co-authorship of manuscript, and primary author on basic and cellular mechanisms;
J.H. Sellin: co-authorship of manuscript; primary author on clinical section; secondary author of pathophysiology.

Address for correspondence: Michael Camilleri, M.D.
Mayo Clinic

Download English Version:

<https://daneshyari.com/en/article/5658679>

Download Persian Version:

<https://daneshyari.com/article/5658679>

[Daneshyari.com](https://daneshyari.com)